Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04781374 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawal of funding

Conditions

Metastatic Prostate Adenocarcinoma
Castration-resistant Prostate Cancer
Prostate Cancer
Prostate Cancer Metastatic

Interventions

DRUG: Neratinib

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]
[object Object]